Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remimazolam
- Development stage
- Approved
- Lead developer
- Paion
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Remimazolam is an ultra short-acting intravenous benzodiazepine used for the induction and maintenance of procedural sedation in adults during short diagnostic or surgical procedures. It acts as a positive allosteric modulator at the benzodiazepine site of gamma-aminobutyric acid type A (GABA(A)) receptors, enhancing the inhibitory effects of GABA in the central nervous system. This results in rapid onset and offset of sedation with predictable pharmacokinetics and minimal tissue accumulation. Remimazolam was developed by PAION AG as an alternative to midazolam, offering faster recovery times and a more favorable safety profile due to its rapid hydrolysis by non-specific tissue esterases into inactive metabolites. Its sedative effects can be reversed with flumazenil[1][4][5][7].
- Brand names
- ByfavoAneremAptimydaRuima
- Other names
- remimazolam besylate
02
Targets
GABAA (Gamma-aminobutyric acid receptor)
Beyond the preview
Go deeper on remimazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remimazolam.